Quantum BioPharma is trading at $2.27, down 5.32%, in a move consistent with broader risk-off trading; no fresh, clearly price-driving company announcement was found for October 22.
- The supplied market context shows the Nasdaq down 2.51% and the S&P 500 down 1.37%.
- Reported summit attendance dates to September 15 and is not a new catalyst.
- The FDA clearance for Lucid-MS Phase 2 was previously announced and does not explain this session’s drop.